Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial.
Israelsen M, Madsen BS, Torp N, Johansen S, Hansen CD, Detlefsen S, Andersen P, Hansen JK, Lindvig KP, Rasmussen DN, Thorhauge KH, Kjærgaard M, Karsdal M, Hansen T, Arumugam M, Trebicka J, Thiele M, Krag A; GALAXY; MicrobLiver Consortia.
Israelsen M, et al. Among authors: trebicka j.
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):523-532. doi: 10.1016/S2468-1253(23)00010-9. Epub 2023 Mar 6.
Lancet Gastroenterol Hepatol. 2023.
PMID: 36893774
Free PMC article.
Clinical Trial.